Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma

Journal of Urology

Volumn 190, Issue 5, 2013, Pages 1662-1667

  Gayed, Bishoy A ^a   Youssef, Ramy F ^a   Bagrodia, Aditya ^a   Kapur, Payal ^a   Darwish, Oussama M ^a   Krabbe, Laura Maria ^a   Sagalowsky, Arthur ^a   Lotan, Yair ^a   Margulis, Vitaly ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biological markers; Carcinoma; Cell cycle proteins; Prognosis; Renal cell

Indexed keywords

CELL MARKER; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN E; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER TISSUE; CELL CYCLE REGULATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 84888638434     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.06.037     Document Type: Article

References (27)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10.
2. Campbell SC and Lane BR: Malignant renal tumors. In: Campbell-Walsh Urology, 10th ed. Edited by AJ Wein, L Kavoussi, AC Novick et al. Philadelphia: Elsevier 2012; pp 1443e4.
3. Flanigan RC, Salmon SE, Blumenstein BA et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655.
4. Shariat SF, Chade DC, Karakiewicz PI et al: Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010; 183: 68.
5. Shariat SF, Karakiewicz PI, Ashfaq R et al: Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112: 315.
6. Chatterjee SJ, Datar R, Youssefzadeh D et al: Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007.
7. Zini L, Porpiglia F and Fassnacht M: Contemporary management of adrenocortical carcinoma. Eur Urol 2011; 60: 1055.
8. Duregon E, Volante M, Giorcelli J et al: Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum Pathol 2013; 44: 822.
9. Jonat W and Arnold N: Is the Ki-67 labelling index ready for clinical use? Ann Oncol 2011; 22: 500.
10. Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1990; 1: 199.
11. Visapaa H, Bui M, Huang Y et al: Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 2003; 61: 845.
12. Rioux-Leclercq N, Turlin B, Bansard J et al: Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000; 55: 501.
13. Tollefson MK, Thompson RH, Sheinin Y et al: Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer 2007; 110: 783.
14. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655.
15. Eble JN: World Health Organization: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press 2004.
16. Edge SB, Byrd DR, Compton CC et al: AJCC Cancer Staging Manual, 7th ed. Philadelphia: Springer 2009.
17. Karam JA, Lotan Y, Karakiewicz PI et al: Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128.
18. Lotan Y: Role of biomarkers to predict outcomes and response to therapy. Urol Oncol 2010; 28: 97.
19. Milde-Langosch K, Bamberger AM, Goemann C et al: Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 2001; 127: 537.
20. Grana X and Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995; 11: 211.
21. Wirapati P, Sotiriou C, Kunkel S et al: Metaanalysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
22. Shariat SF, Ashfaq R, Sagalowsky AI et al: Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007; 177: 481.
23. Youssef R, Kapur P, Shariat SF et al: Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. BJU Int 2012; 110: 961.
24. Bagrodia A, Youssef RF, Kapur P et al: Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. Eur Urol 2012; 62: e27.
25. Shariat SF, Bolenz C, Godoy G et al: Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009; 182: 78.
26. Shariat SF, Chromecki TF, Cha EK et al: Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol 2012; 187: 457.
27. Shariat SF, Zlotta AR, Ashfaq R et al: Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007; 20: 445.